by Elizabeth Kissling | Jan 5, 2010 | Menopause, New Research, Pharmaceutical
As we have often noted here, one of the key reasons the marketing of hormone therapy for menopausal women has been so successful is the misguided belief that menopause is an estrogen-deficiency disease. Among other purported disadvantages of the decline in estrogen...
by Chris Hitchcock | Jan 1, 2010 | Health Care, Menopause, Pharmaceutical
The bioidentical hormone therapy industry has been getting a bad rap lately in the US, and this press release is an example of why. Among other things, the writer confuses estrogen and progesterone, in one paragraph saying their product is a “safe and...
by Elizabeth Kissling | Dec 22, 2009 | Celebrities, Men, Menopause
Guest Post by David Linton, Marymount Manhattan College An earlier re: Cycling post about a clever viral marketing strategy that exploited the notion of male cramps reminded me of some other ways that men have tried to appropriate aspects of the menstrual mythos for...
by Elizabeth Kissling | Dec 18, 2009 | Health Care, Law/Legal, Menopause, Pharmaceutical
You may have heard the news that 23 hormone replacement therapy lawsuits filed by women diagnosed with breast cancer were dismissed by a New York judge this week. Judge Martin Shulman granted Pfizer’s motion to dismiss for two reasons: the plaintiff’s...
by Elizabeth Kissling | Dec 16, 2009 | Internet, Law/Legal, Media, Menopause, Pharmaceutical
That was Zoe Littlepage’s response to Pfizer’s request to a judge that her law firm remove this video press release about Pfizer’s malfeasance regarding cancer risk of Prempro, their menopause hormone therapy drug. The motion reads, in part,...
by Elizabeth Kissling | Dec 13, 2009 | Advertising, Law/Legal, Media, Menopause
There’s a pretty good essay in this weekend’s New York Times (online here Saturday, in print Sunday in the Business section) about how hard Big Pharma has worked to market menopause as an estrogen deficiency disease. In addition to discussion of...
